Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

This study was conducted to determine the maximum tolerated dose and dose-limiting toxicity of irinotecan (CPT-11) administered every 3 weeks to adults with progressive malignant glioma who were treated with enzyme-inducing antiepileptic drug (EIAED) therapy, and to compare the pharmacokinetics with...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Prados, Michael D., Yung, W.K.A., Jaeckle, Kurt A., Robins, H. Ian, Mehta, Minesh P., Fine, Howard A., Wen, Patrick Y., Cloughesy, Timothy F., Chang, Susan M., Nicholas, M. Kelly, Schiff, David, Greenberg, Harry S., Junck, Larry, Fink, Karen L., Hess, Kenneth R., Kuhn, John
Format: Artigo
Langue:Inglês
Publié: Duke University Press 2004
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871968/
https://ncbi.nlm.nih.gov/pubmed/14769140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/S1152851703000292
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires